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CONSPECTUS
P
rotein misfolding has been implicated in a large number of diseases termed protein- folding disorders (PFDs), which
include Alzheimer’s disease, Parkinson’s disease, transmissible spongiform encephalopathies, familial amyloid poly-
neuropathy, Huntington’s disease, and type II diabetes. In these diseases, large quantities of incorrectly folded proteins
undergo aggregation, destroying brain cells and other tissues.
The interplay between ligand binding and hydration is an important component of the formation of misfolded protein spe-
cies. Hydration drives various biological processes, including protein folding, ligand binding, macromolecular assembly, enzyme
kinetics, and signal transduction. The changes in hydration and packing, both when proteins fold correctly or when folding goes
wrong, leading to PFDs, are examined through several biochemical, biophysical, and structural approaches. Although in many cases
the binding of a ligand such as a nucleic acid helps to prevent misfolding and aggregation, there are several examples in which
ligands induce misfolding and assembly into amyloids. This occurs simply because the formation of structured aggregates (such
as protoﬁbrillar and ﬁbrillar amyloids) involves decreases in hydration, formation of a hydrogen-bond network in the secondary
structure, and burying of nonpolar amino acid residues, processes that also occur in the normal folding landscape. In this Account,
we describe the present knowledge of the folding and misfolding of different proteins, with a detailed emphasis on mammalian
prion protein (PrP) and tumoral suppressor protein p53; we also explore how ligand binding and hydration together inﬂuence
the fate of the proteins.
Anﬁnsen’s paradigm that the structure of a protein is determined by its amino acid sequence is to some extent contradicted by the
observation that there are two isoforms of the prion protein with the same sequence: the cellular and the misfolded isoform. The cellu-
lar isoform of PrP has a disordered N-terminal domain and a highly ﬂexible, not-well-packed C-terminal domain, which might account
for its signiﬁcant hydration. When PrP binds to biological molecules, such as glycosaminoglycans and nucleic acids, the disordered seg-
ments appear to fold and become less hydrated. Formation of the PrP-nucleic acid complex seems to accelerate the conversion of
the cellular form of the protein into the disease-causing isoform. For p53, binding to some ligands, including nucleic acids,
would prevent misfolding of the protein. Recently, several groups have begun to analyze the folding-misfolding of the indi-
vidual domains of p53, but several questions remain unanswered. We discuss the implications of these ﬁndings for under-
standing the productive and incorrect folding pathways of these proteins in normal physiological states and in human disease,
such as prion disorders and cancer. These studies are shown to lay the groundwork for the development of new drugs.
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In the year 2009, we commemorate Charles Darwin’s 200th
birthday and 150 years since the publication of the seminal
book On the Origin of Species.
1 Biology has evolved in fasci-
nating and unexpected ways, and most of the general predic-
tions of Darwin’s theory of evolution have been tested at the
molecular level. Chemists, biochemists, and physicists are try-
ing to describe the conformation landscape of biomolecules
through the use of their sophisticated tools, including quan-
tum mechanics, kinetics, and thermodynamics. However, the
understanding of apparently simple processes, such as pro-
tein folding, has so far eluded us. The applications of some of
the laws of chemistry and physics do not always result in suc-
cess, as was brilliantly pointed out by Schro ¨dinger in What is
Life (1944):
2 “... about the structure of living matter, we must
be prepared to ﬁnd it working in a manner that cannot be
reduced to the ordinary laws of Physics”; and that is so
“because the construction is different from anything we have
yet tested in the physical laboratory”.
Schro ¨dinger’s forecasts have become real, and most of our
attempts to frame Biology according to a deterministic view
have failed. This is particularly true in the processes that lead
a biopolymer to evolve in space and time. Water is the ubiq-
uitous background for all these processes, and although it
tended initially to be overlooked, theoreticians and experi-
mentalists have had to take it into account more and more.
3
From enzyme catalysis to cell signaling throughout the differ-
ent compartments in the cell, water activity plays a crucial role.
A protein will fold after successfully sampling the lowest free
energies of the protein folding funnel according to the inter-
actions among the different amino acid residues as well as to
the differential interactions with water molecules (Figure 1).
The protein energy landscape gains considerable complex-
ity with the inclusion of interactions with water.
3 For some pro-
teins, the energy landscape becomes more complicated when
the system drifts into an aggregation pathway, as exempli-
ﬁed in Figure 1. Protein misfolding and aggregation are
involved in more than 30 human diseases.
4 Protein aggrega-
tion also proceeds with changes in hydration similar to fold-
ing and ligand binding.
5 Protein folding intermediates have
been spotted as precursors to the misfolded and aggregated
species. The choice of the folding intermediates that lead into
a native or misfolded conformation will depend on how the
different states are populated, based on their energies, energy
barriers, and exposure of hydrophobic surfaces to the aque-
ous milieu (Figure 1). Homeostasis of cellular proteins is con-
trolled by proteasomes, chaperones, and other folding
assistants that play a crucial role in preventing the deleteri-
ous effects of misfolding.
6 Folding and misfolding/aggrega-
tion are equally driven by dehydration, and therefore, it is
critical to evaluate the contribution of hydration to the forma-
tion of folded and misfolded species. Ligand binding leads to
a decrease in solvent exposure very similar to that observed
when the protein folds or aggregates.
Here, we review how ligand interaction affects protein fold-
ing and misfolding. The effects might be paradoxical; depend-
ing on concentration and the presence of partners, the
outcome can be prevention of misfolding or its acceleration.
2. Hydration in Protein Folding, Misfolding,
and Amyloid Assembly
The importance of hydration for the formation of amyloids has
been deduced from structural studies
7 as well by molecular
dynamics.
8 The use of computer simulations to study protein
aggregation encounters problems due to the complexity of the
system. Using explicit and implicit solvent simulations, a study
with the amyloidogenic -hairpin peptide (109-122) of the
Syrian hamster prion protein allowed the authors to demon-
strate that solvent exposure of hydrophobic surfaces is the
driving force for the folding of the peptide.
8
There are several in vitro studies that address the effects of
water deprivation on the aggregation of proteins.
9,10 Using
model cosolvents, Grudzielanek et al.
10 described how solva-
tional perturbations lead into pronounced and different effects
FIGURE 1. Free-energy landscape of protein folding versus
misfolding. Unfolded proteins (represented in the top of the
diagram) have high conformational entropy and are highly
hydrated. As the proteins evolve in the funnel, the intermediate
species become more structured and less hydrated. Some proteins
face a bifurcation in the landscape, leading to metastable
conformations, which depending on the conditions might stabilize
misfolded and aggregated species.
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insulin. Mukherjee and co-workers
9 utilized reverse micelles
to show that the aggregation rates of two amyloid-forming
peptides increase when hydration is decreased.
As described below, pressure and volumetric approaches
make it possible to assess the effects of hydration and ligands
on the folding and misfolding of proteins.
Hydration Effects on Protein Misfolding and Amyloid
Aggregation as Studied by High Hydrostatic Pressure.
Proteins undergo dissociation and unfolding by pressure
mostly because the ﬁnal states are more hydrated, have fewer
nonhydrated cavities, and, therefore, occupy smaller volumes
5
(Figure 2). For a typical case of protein denaturation, pressure
will shift the equilibrium of the reactants (PN + nH2O) into the
products (PD(H2O)n), where PN and PD are native and denatured
proteins, respectively. The decrease in volume is due to hydra-
tion of newly exposed nonpolar and polar residues as well as
to the loss of free volume arising from packing defects in the
folded structure. High pressure has been used to assess the
underlying mechanisms of protein misfolding and aggre-
gation.
5,11-13 Some ﬁbrillar aggregates are highly sensitive to
pressure, and this sensitivity is related to the inﬁltration of
water molecules into the protein interior during pres-
surization.
5,11
The similar sensitivity to pressure of folded and misfolded
proteins indicates comparable forces maintaining these states,
especially because they have similar water-excluded cavities.
Thus, both the folded and aggregated states will be less
hydrated and have larger speciﬁc volumes (in cm3/mol) than
the unfolded and dissociated states (Figure 2). Early aggre-
gated species and protoﬁlaments always have larger volumes
and are thus sensitive to hydrostatic pressure.
12-16 Although
ﬁbrils might be less hydrated than early aggregates, they are
more stable and have greater contributions from hydrogen
bonds. Thus, much higher pressures would be required to dis-
sociate these aggregates. A typical case is the amyloid ﬁbrils
of 2-microglobulin (2-m), involved in dialysis-related amy-
loidosis, which are not tightly packed; instead, they present a
larger number of cavities than denatured protein.
16 However,
mature amyloid-like ﬁbrils formed from a fragment of the
2-m protein have a smaller partial speciﬁc volume, proba-
bly because of a greater contribution from hydrogen bonds.
16
Similar results had been observed when comparing whole
transthyretin with TTR peptides.
11,13
Pressure can also promote the formation of intermediates
that are prone to aggregation
11,13 (Figure 2). Pressure would
have a reshufﬂing activity, producing intermediates that might
evolve into misfolded/aggregated species under decompres-
sion. For transthyretin, involved in senile systemic amyloido-
sis and in familial amyloidotic polyneuropathy, a less stable
tetramer is formed after decompression.
11,14 More recently,
high pressure was used to explore a potential therapy against
amyloidogenic diseases by trapping the monomer of a non-
amyloidogenic variant (T119M) of transthyretin.
17 Pressure
produced long-lived monomers of T119M. They were mixed
with aggressive mutants of TTR to generate heterotetramers,
which became nonamyloidogenic.
17
3. Prion Protein: A Hydrated Promiscuous
Protein
Transmissible spongiform encephalopathies (TSEs) are rare,
fatal neurodegenerative diseases.
18 The most intriguing fea-
ture of TSEs is that they can be infectious, in addition to the
hereditary and sporadic forms. All TSEs are related to a sin-
gle type of infectious agent that contains isoforms of a con-
stitutive protein known as the prion protein (PrP).
18 The
cellular prion isoform (PrPC) is rich in alpha helices and occurs
naturally in cells of the host, whereas the misfolded form is a
conformational variant of the ﬁrst, rich in -sheets, involved in
transmission of the disease, called the prion scrapie (PrPSc).
18
Mature PrPC is anchored to the outer cell membrane through
a glycosyl phosphatidyl inositol anchor. PrPC has a globular
domain and a highly disordered amino-terminal domain.
18
The physiological function of PrP is still a matter of intense
debate.
FIGURE 2. Hydrostatic pressure effects in different systems.
Pressure acts on proteins by water inﬁltration and shifts the
equilibrium to smaller volumes, and may induce protein
denaturation, protein dissociation, dissociation of protein-nucleic
acid complexes, disassembly of aggregates, including amyloids, and
formation of preamyloidogenic intermediates.
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Hydration and Might Be Promoted by Ligands. The “pro-
tein-only hypothesis” postulates that the PrP is the main agent
responsible for the outbreak of TSEs.
18 The discovery that PrP
knockout mice are resistant to infection by prions
19 is the
main groundwork for this hypothesis. The mechanisms that
lead to conversion of PrPC into PrPSc are still unknown, but
there are several proposed models. Incubation of PrPC with
excess of PrPSc gives protease resistance,
20 suggesting that
PrPSc catalyzes the conversion of PrPC into newly formed PrPSc.
However, it has been suggested by several groups that a still
unknown cofactor might initiate or modulate the conversion
of PrPC to PrPSc.
21-23 This hypothetical molecule would lower
the free-energy barrier that prevents conversion between PrPC
and PrPSc, triggering formation of PrPSc (Figure 3).
Biophysical studies have demonstrated that the transition
between these states involves changes in hydration.
15,24,25
The free-energy and volume diagrams (Figure 3) show that the
cellular isoform is in a metastable conformation, and surpris-
ingly the differences involve larger changes in volume than in
free energy. Studies employing high-pressure Fourier trans-
form infrared (FTIR) and pressure perturbation calorimetry indi-
cated that the cellular PrP isoform is more hydrated and has
a larger solvent-accessible surface area than aggregated
recombinant PrP (rPrP)
15,25 (Figure 3). Molecular dynamics
studies corroborated the role of hydration in the stability and
amyloidogenicity of PrP.
24 Binding of a cofactor (such as
nucleic acid or a glycosaminoglycan) would lead to a decrease
in solvent-accessible surface area and a decrease in the level
of hydration (Figure 3). Below, we focus on the ligand-bind-
ing properties of the prion protein and its implication in hydra-
tion changes in the latter leading to disease progression.
Binding of PrP to Nucleic Acids and Changes in
Hydration. Nucleic acids are now believed to be important
players
26 in prion biology. DNA or RNA molecules would par-
ticipate in prion diseases as cofactors, helping to trigger the
conversion of PrPC into PrPSc (Figure 3). Nandi and Leclerc
showed that recombinant murine prion protein (rPrP) polymer-
izes in a nucleic acid solution.
27 The ﬁrst experimental evi-
dence for a catalytic role of nucleic acids in PrP conversion
was presented by some of us in 2001.
21 We showed that
recombinant prion protein could bind DNA oligonucleotides
with high afﬁnity in vitro. Our main ﬁnding was that the PrP/
nucleic acid complex could act as a catalyst, increasing the
aggregation rate
21 (Figure 3). The structural data obtained
from small-angle X-ray scattering (SAXS) and nuclear mag-
netic resonance (NMR) measurements showed that rPrP inter-
acts with DNA through both the globular and disordered
domains.
28 The changes in NMR chemical shifts suggest a
restructuring of the protein upon DNA binding and decrease
of hydration.
28
PrP can also bind RNA molecules.
29-32 Highly structured
RNA molecules bind human rPrP with high afﬁnity.
30 PrP can
also form structures similar to retroviral proteins, therefore
possessing RNA-binding chaperone characteristics, likely par-
ticipating in nucleic-acid metabolism.
33 The interaction of PrP
with RNA was shown to stimulate the conversion of PrPC to
PrPRes (protease-resistant PrP) in hamster brain homogenates,
and treatment of these homogenates with RNase inhibited the
conversion.
22 Lately, synthetic RNAs were used to generate
PrPRes formation.
32 This result is consistent with our DNA-bind-
ing results suggesting that nucleic acids could be involved in
prion conversion.
21 Intracerebral inoculation of a mixture of
synthetic RNAs, puriﬁed PrP, and copuriﬁed lipids caused neu-
rodegeneration in wild-type hamsters.
32
Full-length rPrP interacts with RNA at the disordered and
highly hydrated N-terminus, undergoing aggregation and los-
ing most of its R-helical content.
31 NMR measurements with
a synthetic RNA sequence showed that the soluble portion of
PrP recovered most of its original fold, but with distinct
changes in the NMR HSQC spectrum.
31 The aggregates
derived from interaction of PrP with RNA extracted from neu-
roblastoma cells were highly cytotoxic.
31 In contrast, com-
FIGURE 3. Energy and volume diagram of PrP misfolding. PrPC
(left) can misfold into an isoform rich in -sheet structure capable of
forming toxic and infectious aggregates (PrPSc) (right). The transition
between the species is separated by a large energetic barrier. I and
U represent intermediate and unfolded states, respectively. An
adjuvant factor would lower the free-energy barrier, triggering
formation of PrPSc. PrPC has a larger solvent-accessible surface area
than the misfolded/aggregated species, and the folding pathway
also exhibits a kinetic barrier in the activation volume (inset,
modiﬁed from ref 15). The pressure-denatured states of R-rPrP (PrPC)
and -rPrP (PrPSc-like) are denoted as U and U′, respectively.
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RNA structure needed for prion binding is still unknown, but
the high ﬂexibility of such molecules is certainly important for
these interactions. It also seems crucial to the interaction
changes in hydration of the protein itself that would decrease
the solvent accessibility (Figure 3).
In the past decade, noncoding RNAs (ncRNA) have been
shown to act in post-translational regulation. The ﬁnding that
PrP interacts with nucleic acid with likely NA chaperone activ-
ities
33 raises the possibility that PrP might have some effects
in the processing of ncRNA. In fact, recent studies showed that
cytoplasmic PrP induced large ribonucleoprotein particles,
34
with potential function in post-transcriptional regulation. The
participation of a nucleic acid in prion conversion would be a
rare event because a seed of misfolded material would also
be needed. Recombinant PrP can also translocate DNA to the
intracellular space and promote DNA expression.
35 A puta-
tive nucleic acid chaperone function for PrP raises the ques-
tion of how interaction with nucleic acids could contribute to
the sporadic cases of prion diseases.
Binding of PrP to Glycosaminoglycans and Potential
Therapeutic Approaches to Prion Diseases. Glycosami-
noglycans (GAGs) have been implicated in many conforma-
tional diseases. Heparan sulfate was found in amyloid plaques
in TSEs.
36 GAGs bind PrPC both in its soluble form and at the
cell surface,
37,38 and other studies showed that sulfated
polysaccharides can inhibit the accumulation of PrPRes in cells
infected with scrapie.
38 Moreover, it was shown that sulfated
GAGs could inhibit the polymerization of prion peptides into
amyloid ﬁbrils.
39 Thus, interaction of PrP (PrPC and/or PrPSc)
with endogenous GAGs might be needed for PrPSc propaga-
tion,
40 and exogenous GAGs might act as inhibitors, block-
ing the interaction of PrP with endogenous proteoglycans. In
this respect, GAGs would act as some nucleic acids do
26 by
reducing the access of the solvent to the protein surface.
A great variety of compounds have been tested in an effort
to ﬁnd agents that reverse or prevent the formation of PrPSc.
Degenerate phosphorothioate oligonucleotides reduce PrPSc
formation in vivo.
41 DNA thioaptamers bind with high afﬁn-
ity to different mammalian prion proteins
41,42 and have great
potential as antiprion agents. GAGs are also considered as
promising compounds for prion diseases.
39,43
4. Misfolding of p53 and Cancer
When cells are subjected to stress, p53 works as a tran-
scription factor, resulting in cell cycle arrest or apoptosis.
44
Failure of these responses leads into uncontrolled cell cycle.
p53 function is lost in more than 50% of human cancers,
making it an appealing target for cancer therapies. p53 is
a modular protein containing an N-terminal transactivation
domain, followed by a proline-rich region, a central DNA-
binding domain (p53C), a tetramerization domain, and a C
terminus.
45 The central or core domain of p53 (p53C), com-
prising residues 94-312, is responsible for speciﬁc DNA
interactions,
45 and 97% of the point mutations in p53 are
in this domain.
An aggravating factor to the misfolding of p53 caused by
single amino acid mutations is the negative dominance
property: several p53 mutants (translated from a single
mutant allele) are able to drive wild-type p53 protein (trans-
lated from the remaining wild-type p53 allele) into a mutant
conformation,
46 in a way that resembles the action of the
prion protein.
p53C is a relatively unstable protein undergoing easily
chemical, thermal, and pressure denaturation.
47-50 Inter-
estingly, p53C loses its DNA-binding activity spontaneously
at 37 °C in vitro due to a kinetic partitioning between fold-
ing and misfolding pathways of the protein.
47 Recently, we
found that the interaction with a cognate DNA sequence
stabilizes p53 and prevents aggregation of the protein into
an amyloid-like structure
51(Figure 4). Sequence-speciﬁc
DNA also stabilized full-length p53. The effects of cognate
DNA could be simulated by high concentrations of
osmolytes, implying that the stabilization is caused by water
exclusion. We propose that aptameric nucleic acids can be
used as therapeutic approaches to prevent misfolded spe-
cies of p53 and treat cancer
51 (Figure 4).
The Intriguing Amyloid Potential of p53. Formation
of amyloid-like aggregates has been described for the
core,
49 for the tetramerization,
52,53 and for the transactiva-
tion
54 domains of p53. Rigacci and co-workers
54 elegantly
demonstrated that the p53 N-terminal domain aggregates
into amyloid assemblies that exhibit cytotoxicity. We found
that the wild-type p53C can form ﬁbrillar aggregates.
49 An
intermediate oligomer of p53C was also observed during
equilibrium and kinetic folding/unfolding transitions.
55
Annular and ﬁbrillar aggregates of p53C were toxic to
cells.
49 The hot-spot mutant R248Q also had a tendency to
aggregate. Thus, the ﬁbrillogenesis of p53 might contrib-
ute to its loss of function and seed the accumulation of con-
formationally altered protein in cancerous cells (Figure 4D).
Several carcinomas exhibit abnormal accumulation of
wild-type or mutant tumor suppressor protein p53 either in
the cytoplasm or in the nucleus of the cell.
56 Evidence that
the three domains of p53 form amyloid-like aggregates is
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amyloid formation might participate in the malignant pro-
cess. Aggregation of p53 would act as a sink to sequester
native protein into the inactive conformation, replicating the
structural information, very much like a prion (Figure 4D).
Hot-spot mutations of p53, related to malignant tumors,
usually destabilize the folded conformation,
45,47 exposing
hydrophobic surfaces to water, and we did ﬁnd that they
have a greater tendency to aggregate.
49 Because this aggre-
gation is likely to include wild-type subunits, it could be the
basis for the negative dominance of p53 mutants.
46 The
search for molecules that preclude the formation of the mis-
folded conformation, which may ultimately lead to the pre-
vention of tumor development, is a major goal in cancer
research. The use of aptameric nucleic acids could be a
good alternative to prevent aggregation and to rescue activ-
ity
51 (Figure 4). A more stable variant of p53 would shift the
equilibrium toward the soluble and active form of the
protein.
5. Nucleic-Acid Effects on Other
Amyloidogenic Proteins
The effects of nucleic acids on the aggregation and mis-
folding properties are not restricted to prion protein
26 and
p53.
51 For all the cases, the binding seems to be driven by
decreases in the surface exposed to the aqueous environ-
ment. The replication initiator protein of Pseudomonas
pPS10 plasmid (RepA) aggregates into amyloids.
57 DNA
induced the aggregation of one of the domains of RepA
into amyloids, which might have a role in the negative reg-
ulation of plasmid replication. However, DNA was not
present in ﬁbrils, similar to what we found for the interac-
tion of PrP with DNA.
21
In the case of R-synuclein, involved in Parkinson’s dis-
ease, it has been found that DNA stimulates formation of
ﬁbrils.
58,59 There was a parallel between the effects of DNA-
binding and osmolytes in inducing ﬁbrillation.
59 These
results are similar to that found with DNA-induced stabili-
zation of p53C, which in turn resembles the stabilization
FIGURE 4. Stabilization of p53C upon sequence-speciﬁc DNA binding and recovery of misfolded aggregated species of p53C. (A)
Structure of p53C bound to DNA (PDB entry 2ABY). (B) Full-length p53 is stabilized against pressure denaturation upon DNA binding as
measured by ﬂuorescence: p53 (blue circles), consensus-bound p53 (red squares), and poly(GC)-bound p53 (green triangles). Open
symbols are values after return to atmospheric pressure. (C) Cognate DNA rescues the native conformation of p53C after misfolding
and aggregation. Fluorescence of wild-type p53C at atmospheric pressure (solid black line); after the ﬁrst cycle of pressurization in the
absence of DNA (red line); after DNA addition at atmospheric pressure (blue line); and after the second pressure cycle in the presence
of DNA (green line). (D) Proposed model for p53C aggregation. Conversion of native, active p53 (blue circles) into aggregates (red
squares) in the cytoplasm (upper panels). Nuclear DNA is represented in purple. Adapted from refs 49 and 51.
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52 Formation
of R-synuclein ﬁbrils is driven by exclusion of molecules of
water, as clearly shown by pressure studies of the ﬁbrils.
11
6. Overview and Future Perspectives
At the end of his book Protein Interactions, published in
1992,
60 Gregorio Weber wrote that “Future knowledge of
the relation of protein function to structure and dynamics
is much more likely to come from the comparative study of
the proteins than from their study as isolated entities to
which elementary physics and chemistry are applicable.” To
some extent, his words reinforce Schrodinger’s statement
that biomolecules are quite complex entities.
2 The great
challenge in Biology for the next decades will be to dis-
cover how interactions among different biomolecules and
with solvent occur in space and time in the cellular con-
text. Even at one of the lowest hierarchical levels, such as
the protein folding, understanding the frequent failure of
polypeptides to reach the native state requires that we com-
prehend the interactions of a plethora of intermediate states
with ligands and the solvent.
5 Here we exempliﬁed this
quite well with the prion protein, p53, and other amy-
loidogenic proteins.
For prions, they seem to have other accomplices (likely
nucleic acids and GAGs) that chaperone their activity in con-
verting the cellular form of the protein into the disease-
causing isoform. There are, however, many questions that
remain to be explored. The ability of the prion protein to
bind nucleic acids may have broader implications for its
native function than for disease. The great abundance of
RNA in the cytosol that acts in a variety of cellular processes
may hint at the physiological target of prion protein.
In the case of p53, it needs to interact with several other
proteins to exert its functions, which contribute to p53’s
conformation and afﬁnity for its target DNA. In the same
manner, post-translational modiﬁcations likely interfere with
protein folding. Another level of complexity for p53 fold-
ing involves p53 mutants that can alter the conformation of
the wild-type protein either by forming heterotetramers or
by aggregation, converting the wild-type monomer into an
inactive form, as described for prions. The comprehension
of p53 folding/misfolding may shed light on the mecha-
nisms of p53 regulation and ultimately the cell’s fate in
tumorigenic processes.
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